Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $9.00 at Chardan Capital
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its price objective boosted by Chardan Capital from $7.00 to $9.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 232.10% from the company’s current price. Several other […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its price objective boosted by Chardan Capital from $7.00 to $9.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 232.10% from the company’s current price. Several other […]
